Capecitabine
- Generic Name
- Capecitabine
- Brand Names
- Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22FN3O6
- CAS Number
- 154361-50-9
- Unique Ingredient Identifier
- 6804DJ8Z9U
- Background
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
- Indication
Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemother...
- Associated Conditions
- Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer
- Associated Therapies
- Chemotherapy
Radiation Therapy With Capecitabine in Rectal Cancer
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2008-01-10
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT00176787
- Locations
- 🇺🇸
University of Michigan Cancer Center, Ann Arbor, Michigan, United States
Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma
- Conditions
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2007-12-21
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 37
- Registration Number
- NCT00165217
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Navelbine and Capecitabine in the Treatment of Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2013-02-07
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 40
- Registration Number
- NCT00153907
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Evaluation of Tumor Factors in Breast Cancer Treated With Docetaxel and Capecitabine
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2012-02-07
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT00156312
- Locations
- 🇺🇸
University of Michigan Cancer Center, Ann Arbor, Michigan, United States
Oxaliplatin and Capecitabine Versus Follow-up After Resection of Colorectal Liver Metastases
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2009-12-25
- Lead Sponsor
- Arbeitsgruppe Lebermetastasen und Tumoren
- Target Recruit Count
- 384
- Registration Number
- NCT00156975
- Locations
- 🇩🇪
Universitaetsklinikum Essen, Klinik für Allgemein- und Transplantationschirurgie OPZ II, Essen, Germany
🇩🇪Universitaetsklinikum Carl Gustav Carus, Medizinische Klinik, Dresden, Sachsen, Germany
🇩🇪Klinik für Allgemein- und Gefäßchirurgie , J. W. Goethe Universität, Frankfurt Am Main, Germany
Study of Oxaliplatin, Capecitabine and Bevacizumab as First Line Treatment for Patients With Advanced Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2014-07-29
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 63
- Registration Number
- NCT00159432
- Locations
- 🇺🇸
U.S.C./Norris Comprehensive Cancer Center, Los Angeles, California, United States
Docetaxel Plus Capecitabine in Newly Diagnosed Localized or Locally Advanced Prostate Cancer
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2015-01-21
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT00151047
- Locations
- 🇺🇸
Wayne State University, Detroit, Michigan, United States
🇺🇸The University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
TBP Study With Capecitabine Plus Minus Trastuzumab
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2011-02-23
- Lead Sponsor
- German Breast Group
- Target Recruit Count
- 482
- Registration Number
- NCT00148876
- Locations
- 🇩🇪
Johann Wolfgang Goethe Universität, Universitätsfrauenklinik, Frankfurt / Main, Hessen, Germany
Capecitabine in Women With Operable Breast Cancer
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2015-11-11
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 80
- Registration Number
- NCT00148720
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Faulkner Hospital, Boston, Massachusetts, United States
A Study of a New Combination and Schedule of Chemotherapy Drugs for the Treatment of Head and Neck Cancer
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2014-04-17
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT00148122
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.